^
Association details:
| Biomarker: | ER positive + PGR negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | ORIN1001 (ERN1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.
Published date:
05/25/2023
Excerpt:
For combination therapy with Abraxane, a PR was observed in one ER+/PR-/HER2- breast cancer pt at 300 mg ORIN1001 and SD was observed in 5 of 13 pts….The proposed RP2D is estimated to be 500 mg and 300 mg ORIN1001 for single agent and in combination with Abraxane, respectively. Early efficacy data with ORIN1001 demonstrate clinical responses (SD and PR) in multiple pts with heavily-pretreated advanced solid tumors as a single agent or in combination with Abraxane in breast cancer patients.
Secondary therapy:
paclitaxel
DOI:
10.1200/JCO.2023.41.16_suppl.1092
Trial ID:
